1. Bupropion SR for Relapse Prevention: A 'Slips-Allowed' Analysis
- Author
-
Raymond Niaura, Jonathan White, Michael J. Durcan, David P.L. Sachs, Nancy A. Rigotti, David Gonzales, and J. Andrew Johnston
- Subjects
musculoskeletal diseases ,Bupropion ,medicine.medical_specialty ,Health (social science) ,Social Psychology ,business.industry ,medicine.medical_treatment ,Public Health, Environmental and Occupational Health ,Retrospective cohort study ,Bupropion sr ,Relapse prevention ,Placebo ,law.invention ,body regions ,Clinical trial ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Smoking cessation ,business ,medicine.drug - Abstract
Objective To assess the efficacy of bupropion SR on smoking abstinence using a "slips allowed" analysis. Methods Retrospective analysis, which did not consider brief episodic "slips" as a return to regular smoking, of data from a multicenter, randomized, doubleblind, placebo-controlled relapse prevention study. Results Using a slips-allowed analysis, median time to relapse on bupropion SR was 65 weeks versus 30 weeks on placebo. This is compared to 32 and 20 weeks, respectively, using a traditional analysis not allowing for slips. Conclusion Bupropion SR is efficacious for the prevention of smoking relapse. A slips-allowed analysis may provide a more clinically relevant assessment of efficacy.
- Published
- 2004
- Full Text
- View/download PDF